Clinical success of complex biological therapies: be careful what you wish for..
作者信息
Brenner Malcolm K
出版信息
Mol Ther. 2010 Oct;18(10):1737-8. doi: 10.1038/mt.2010.204.
Abstract
摘要
相似文献
1
Clinical success of complex biological therapies: be careful what you wish for..
Mol Ther. 2010 Oct;18(10):1737-8. doi: 10.1038/mt.2010.204.
2
Editorial for ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective.
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S1. doi: 10.1016/j.cmi.2018.04.029.
3
Genome editing-based HIV therapies.
Trends Biotechnol. 2015 Mar;33(3):172-9. doi: 10.1016/j.tibtech.2014.12.006. Epub 2015 Jan 15.
4
Translating stem cell therapy to the clinic: déjà vu all over again.
Mol Ther. 2009 Oct;17(10):1659-60. doi: 10.1038/mt.2009.215.
5
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction).
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S2-S9. doi: 10.1016/j.cmi.2018.01.029. Epub 2018 Feb 7.
6
Immunology of Gene and Cell Therapy.
Mol Ther. 2020 Mar 4;28(3):691-692. doi: 10.1016/j.ymthe.2020.01.024. Epub 2020 Feb 4.
7
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways).
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S41-S52. doi: 10.1016/j.cmi.2017.12.027. Epub 2018 Feb 7.
8
Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.
Am J Clin Dermatol. 2013 Aug;14(4):327-33. doi: 10.1007/s40257-013-0021-0.
9
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4).
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S83-S94. doi: 10.1016/j.cmi.2018.03.022. Epub 2018 Mar 20.
10
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).
Clin Microbiol Infect. 2018 Jun;24 Suppl 2(Suppl 2):S95-S107. doi: 10.1016/j.cmi.2018.01.030. Epub 2018 Feb 7.
Zotero 插件